Navigation Links
Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
Date:5/3/2011

www.anthera.com/">www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)Three Months Ended March 31,20112010OPERATING EXPENSE:Research and development

$
,316,758$
5,241,814General and administrative

2,339,8821,224,110Total operating expense

18,656,6406,465,924LOSS FROM OPERATIONS:

(18,656,640)(6,465,924)OTHER INCOME (EXPENSE):Other expense and interest income, net

90,935(4,637,868)Total other income (expense)

90,935(4,637,868)NET LOSS

$  (18,565,705)$  (11,103,792)Net loss per share--basic and diluted

$
(0.56)$
(0.83)Weighted-average number of shares used in
per share calculatio
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
2. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
3. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
4. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
5. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
6. Anthera Announces Update Call Regarding Vial Problems
7. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
8. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
9. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
10. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
(Date:5/4/2015)...  Makindus, Inc. a specialty pharmaceutical development company focused ... (EMA) has granted orphan drug designation for their lead ... "We are extremely pleased to now have orphan ... place for Europe . This complements ... United States for which orphan designation has ...
(Date:5/4/2015)... , May 4, 2015  By looking ... possible to distinguish between two very different conditions ... Theodore Henderson , MD, PhD., a ... complex cases, this study can help ... and therefore treatment options, for Post-Traumatic Stress Disorder ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3
... DIEGO, Dec. 1 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... completed preclinical study has affirmed the bioequivalence and comparable ... Pharmaceuticals, ADVENTRX,s partner for ANX-514 in South Korea, independently ... "Our independent confirmation of the bioequivalence and comparable overall ...
... , REDWOOD CITY, Calif., Dec. 1 Codexis, Inc. today ... its second agreement this year with Teva Pharmaceutical Industries Ltd., ... covers three undisclosed pharmaceutical products. Codexis announced an earlier ... agreement, Teva will use Codexis biocatalysis technology for key process ...
Cached Medicine Technology:ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Codexis Expands Collaboration with Teva 2
(Date:5/5/2015)... BioFit Engineered Products , a ... models from its two latest lines at NeoCon 2015, ... Chicago. Headlining the company’s exhibit will be new Pro ... as well as the unveiling of the fifth model ... Ed Metzger will deliver in-booth presentations each day of ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 With the ... clothing and enjoying the feel of warm breezes on bare ... to strategies on how to look their best in shorts, ... “More and more people are turning to laser treatments for ... aesthetician of Simply Posh Aesthetic Spa . “They're all ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 “We currently have larger ... states Marta Phillips, owner of SunGrubbies.com. “We felt it was ... to find a fashionable sun hat in an extra large size ... event.” , Fashionable derby sun hats such as the ... brim are now available in an extra large size , ...
(Date:5/5/2015)... San Francisco, Calif. (PRWEB) May 05, 2015 ... available online but these have focused primarily on personal ... the National Directory of Insurance (NDOI.com) has ... licensed insurance agents in the U.S. to present their ... public marketplace. , The result is significant and two-fold. ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 No ... The Centers for Disease Control and Prevention cite ... effects our everyday life: “Poor indoor air quality (pollution) can ... to chronic heart and lung problems and cancer.” , Toxic ... swallow them in contaminated food or water, or in some ...
Breaking Medicine News(10 mins):Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 3Health News:Laser Hair Removal: Tips for Summertime Grooming 2Health News:Laser Hair Removal: Tips for Summertime Grooming 3Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Launches Their New Extra Large Size Fashion Sun Hats Collection 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 3Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 3
... to reasearchers, a hormone is released into the blood after ... might be supportive in treating obesity. The reason for feeling ... hormone called PYY3-36 //which acts on the brain to produce ... report on the first human trial of PYY3-36. ...
... could be saved each year, if only everyone over the ... experts, Dr. Gregory Poland fe that universal vaccination in three ... by 40 to 50 per cent. Clearly vaccination can be ... per cent. ,Dr Poland proposes some changes to ...
... to the dimpled, 'orange peel' skin on the thighs, buttocks, ... all have a beneficial effect on the appearance of cellulite ... body's natural way of storing fat in women and occurs ... a dermatologist at the University of California, cellulite is now ...
... According to recent update, people with type 2 diabetes ... able to safely reduce their risk for heart disease ... runs counter to previous research, which showed niacin adversely ... the researchers used high doses of the medication. ...
... in lessening the symptoms of fibromyalgia.,Researchers at Pole Hospital, ... with fibromyalgia, a painful muscular condition whose causes are ... to routine sessions of graded aerobic exercise, supervised by ... of those in the exercise group rated themselves as ...
... feel, that we need to learn more about ... microwaves play an increasing role in everyday life - ... pagers, and text messengers. ,We often walk past ... other words, we are bathed in an invisible 'electrosmog', ...
Cached Medicine News:
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 9.0 mm and length 7.5 mm....
Medicine Products: